Next 10 |
home / stock / asln / asln articles
Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market trading after the company disclosed a strategic partnership with ...
New positive data from an additional analysis of dupilumab-experienced patients treated with eblasakimab 400mg, weekly over 16 weeks further supp...
ASLAN management will present new data from the interim analysis of the TREK-DX study Register here to attend the webinar event on May 7, 2024 at...
SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceutical (NASDAQ:ASLN), a clinical-stage, immunology-focused bio...
New Composition of Matter Patent for farudodstat would strengthen intellectual property protection and provide commercial exclusivity for farudod...
SAN MATEO, Calif. and SINGAPORE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused bio...
Following the successful TREK-AD Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, process is underway to identify potential...
SAN MATEO, Calif. and SINGAPORE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology focused bio...
Head-to-head study between eblasakimab and dupilumab in skin biopsies from atopic dermatitis (AD) patients confirm eblasakimab's differentia...
News, Short Squeeze, Breakout and More Instantly...
ASLAN Pharmaceuticals Limited Company Name:
ASLN Stock Symbol:
NASDAQ Market:
ASLAN Pharmaceuticals Limited Website:
A look at the top 10 most actives in the United States Zoomcar Holdings Inc. (ZCAR) rose 58.3% to $0.2162 on volume of 130,087,791 shares Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.1863 on volume of 71,767,970 shares SMX (Security Matters) Public Limited Company (SMX) rose 17.1...
2024-07-02 09:02:05 ET ASLAN Pharmaceuticals Ltd (ASLN) announced stock split at a ratio of 1-for-8 on 2024-07-03 ... Full story available on KlickAnalytics.com
Translational data presented during a late-breaker poster session from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD indicates that eblasakimab performed better than dupilumab in improving airway function and ...